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Abstract
Background: Tibia fracture followed by cast immobilization in rats evokes nociceptive, vascular, epidermal, and
bone changes resembling complex regional pain syndrome (CRPS). In most cases, CRPS has three stages. Over time,
this acute picture, allodynia, warmth, and edema observed at 4 weeks, gives way to a cold, dystrophic but still
painful limb. In the acute phase (at 4 weeks post fracture), cutaneous immunological and NK1-receptor signaling
mechanisms underlying CRPS have been discovered; however, the mechanisms responsible for the chronic phase
are still unknown. The purpose of this study is to understand the mechanisms responsible for the chronic phases
of CRPS (at 16 weeks post fracture) at both the peripheral and central levels.
Methods: We used rat tibial fracture/cast immobilization model of CRPS to study molecular, vascular, and nociceptive
changes at 4 and 16 weeks post fracture. Immunoassays and Western blotting were carried out to monitor changes in
inflammatory response and NK1-receptor signaling in the skin and spinal cord. Skin temperature and thickness were
measured to elucidate vascular changes, whereas von Frey testing and unweighting were carried out to study
nociceptive changes. All data were analyzed by one-way analysis of variance (ANOVA) followed by Neuman-Keuls
multiple comparison test to compare among all cohorts.
Results: In the acute phase (at 4 weeks post fracture), hindpaw allodynia, unweighting, warmth, edema, and/or
epidermal thickening were observed among 90 % fracture rats, though by 16 weeks (chronic phase), only the
nociceptive changes persisted. The expression of the neuropeptide signaling molecule substance P (SP), NK1 receptor,
inflammatory mediators TNFα, IL-1β, and IL-6 and nerve growth factor (NGF) were elevated at 4 weeks in sciatic
nerve and/or skin, returning to normal levels by 16 weeks post fracture. The systemic administration of a peripherally
restricted IL-1 receptor antagonist (anakinra) or of anti-NGF inhibited nociceptive behaviors at 4 weeks but not
16 weeks. However, spinal levels of NK1 receptor, TNFα, IL-1β, and NGF were elevated at 4 and 16 weeks, and
intrathecal injection of an NK1-receptor antagonist (LY303870), anakinra, or anti-NGF each reduced nociceptive
behaviors at both 4 and 16 weeks.
Conclusions: These results demonstrate that tibia fracture and immobilization cause peripheral changes in
neuropeptide signaling and inflammatory mediator production acutely, but central spinal changes may be more
important for the persistent nociceptive changes in this CRPS model.
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Background
Complex regional pain syndrome type I (CRPS) is an
often chronic pain condition characteristically dispropor-
tionate to the inciting event. The syndrome develops
after a range of injuries including fractures, soft tissue
trauma to the extremities, or as a consequence of a
separate disease process like stroke or myocardial infarc-
tion [1]. In most cases, CRPS has three stages, but CRPS
does not always follow this pattern. In many patients,
the early symptoms are of a warm, erythematous, swol-
len, painful limb, the so-called “warm phase” thought
to be supported by neurogenic inflammation [2–4]. In
the acute phase, cutaneous immunological mechanisms
underlying CRPS have been discovered, including auto-
immunity [5], keratinocyte activation, proliferation, and
expression of inflammatory mediators such as tumor
necrosis factor alpha (TNFα), interleukin-1 beta (IL-
1β) and interleukin-6 (IL-6), nerve growth factor
(NGF), and mast cell activation [6, 7]. Substance P (SP),
acting through up-regulated neurokinin 1 (NK1) receptors
expressed in the peripheral tissues of the involved limb,
appears to be a key signaling molecule supporting the
signs and symptoms of CRPS [8, 9]. Over time, however,
this acute picture gives way to a cold, dystrophic but still
painful limb. Changes with origins clearly within the
central nervous system (CNS) such as emotional prob-
lems, cognitive changes, and movement disorders can be
observed in some patients [10, 11]. Prospective studies
have observed a gradual spontaneous resolution of CRPS
symptoms and signs in distal limb fracture cases, with 66
to 80 % of cases completely resolving by 6 months after
injury [12–15]. The mechanisms supporting the chronic
phases of CRPS are still very poorly understood.
The fracture/cast immobilization rodent model of CRPS
displays the principal signs of CRPS including warmth,
edema, enhanced neurogenic extravasation, epidermal
hypertrophy, bone loss, and nociceptive changes [16–19].
These animals also show an evolution of signs over time
to resemble the more chronic phases of CRPS in humans
[17]. Using this model, it has been shown that neuropep-
tide signaling is particularly important for nociceptive
sensitization and cytokine generation in the affected limb
4 weeks after fracture when acute phase changes are
present. However, it is unclear whether these peripheral
mechanisms continue to contribute to the persistent signs
of CRPS in the chronic phases of the model, or whether
central changes become the predominant mechanistic
factors. Some evidence from CRPS patients suggests that
peripheral inflammatory mechanisms may fade with time
including levels of skin cytokines and mast cell abundance
in skin [6, 20].
Therefore, in the present study, we hypothesized that
the enhanced vascular permeability, edema, warmth, and
nociceptive sensitization observed in the rodent CRPS
model could be attributed to enhanced peripheral
neuropeptide and cytokine signaling in the acute phase,
whereas the persistent allodynia observable 16 weeks post
fracture would be attributable to NK1 receptor activation
and neuroinflammation in the spinal cord. Such findings
might enhance our understanding of the evolution of
CRPS over time and may suggest approaches to tailoring
CRPS treatment to its duration and clinical features.
Methods
These experiments were approved by our institute’s
Subcommittee on Animal Studies and followed the guide-
lines of the International Association for the Study of Pain
(IASP) [21]. Adult (9 months old) male Sprague Dawley
rats (Simonsen Laboratories, Gilroy, CA, USA) were used
in all experiments. The animals were housed individually
in isolator cages with solid floors covered with 3 cm of soft
bedding and were fed and watered ad libitum. During the
experimental period, the animals were fed Teklad Global
18 % Protein Rodent Diet (www.Envigo.com, Madison,
WI.) and were kept under standard conditions with a
12-h light–dark cycle. For all experiments, animals were
randomly assigned to study groups, and observers were
blinded to treatment conditions such as drug injections.
Surgery and recovery
Tibial fracture was performed under isoflurane anesthesia
as we have previously described [17]. The right hindlimb
was wrapped in stockinet (2.5 cm wide), and the distal
tibia was fractured using pliers with an adjustable stop
that had been modified with a 3-point jaw. The hindlimb
was wrapped in casting tape so the hip, knee, and ankle
were flexed. The cast extended from the metatarsals of the
hindpaw up to a spica formed around the abdomen. To
prevent the animals from chewing at their casts, the
cast material was wrapped in galvanized wire mesh.
The rats were given subcutaneous saline and bupre-
norphine (0.03 mg/kg) immediately after the procedure
and on the next day after fracture for postoperative
hydration and analgesia. At 4 weeks, the rats were
anesthetized with isoflurane, and the cast removed with a
vibrating cast saw. All rats used in this study had mechan-
ical union at the fracture site after 4 weeks of casting. To
study changes in the chronic phase, after cast was
removed at 4 weeks, fracture rats were allowed to recover
in cages until 16 weeks after fracture prior to behavioral
and biochemical testing.
Drugs
The NK1 receptor antagonist LY303870 was a generous
gift from Dr. L. Phebus (Eli Lily Company, Indianapolis,
IN, USA). This compound has nanomolar affinity for the
rat NK1 receptor, has no affinity for 65 other receptors
and ion channels, has no sedative, cardiovascular or core
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body temperature effects in rats at systemic doses up to
30 mg/kg, and is physiologically active for 24 h after a
single systemic dose of 10 mg/kg [22–24]. The doses of
systemic and intrathecal LY303870 used in the study
were based on our prior studies demonstrating analgesic
efficacy with these doses in the 4-week post-fracture rat
model [17, 25]. LY303870 (30 mg/kg/day, i.p.) was
administered daily for 7 days and one final dose at 1 h
prior to testing [24] or via intrathecal injection (10 μl at
20 μg/μl, 30 min prior to testing). All testing was carried
out at 4 and 16 weeks after tibia fracture.
A naturally occurring IL-1-receptor antagonist (IL-1ra)
modulates the activity of IL-1β in vivo. Anakinra, a re-
combinant met-human IL-1ra (r-metHuIL-1ra, Kineret,
Amgen) that binds to the IL-1 type I receptor (IL-1 RI),
effectively inhibits IL-1β signal transduction [26]. To test
the hypothesis that IL-1β signaling mediates the vascular
and nociceptive changes observed after tibia fracture in
rats, osmotic pumps (model 2ML4, Alzet) were used for
delivering anakinra IL-1ra. The pumps were inserted
subcutaneously over the rat’s back. Based on previous
studies using IL-1ra in rodents [27–29] and based on
discussions with lead scientists from Amgen, it was
previously decided to administer 10 mg/kg/day of ana-
kinra via subcutaneous pump for 28 days prior to testing
at 4 weeks post fracture. During the present study, we
discovered that, at 16 weeks, systemic treatments with
LY303870 and anti-NGF lost more than 50 % of their
anti-nociceptive effects observed at 4 weeks post frac-
ture. In addition, skin cytokines at 16 weeks, including
IL-1β, declined from 4 weeks post fracture, but spinal
cord cytokine concentrations at 16 weeks remained high
and close to the peak concentration at 4 weeks post
fracture. These data suggested that SP signaling and
inflammation in the spinal cord at the central level might
contribute to nociceptive abnormalities at 16 weeks. To
demonstrate the effects of anakinra on fracture-induced
nociceptive abnormalities at the spinal cord level, ana-
kinra was administered via a single intrathecal injection
(10 μl at 10 μg/μl) at 1 h prior to testing at 4 and 16 weeks
post fracture. As a comparison at the systemic level,
100 mg anakinra/kg, one dose i.p. was injected 1 h prior
to testing at 16 weeks post fracture. All testing was
carried out at 4 and 16 weeks after tibia fracture.
The anti-NGF antibody muMab 911 (Rinat Laborator-
ies, Pfizer Inc.) is a TrkA immunoglobulin G (TrkA-IGG)
fusion molecule that binds to the NGF molecule, thus
blocking the binding of NGF to the TrkA and p75 NGF
receptors and inhibiting TrkA autophosphorylation [30].
Pharmacokinetic and behavioral experiments in rodents
indicate that muMab 911 has a terminal half-life of 5 to
6 days in plasma and that a 10 mg/kg dose administered
every 5 or 6 days reduces nociceptive behavior in a variety
of rodent chronic pain models [31–34]. Based on these
data and discussions with lead scientists at Rinat, it was
determined to administer muMab 911 via a single sub-
cutaneous injection (10 mg/kg) 7 days prior to testing or
via a single intrathecal injection (10 μl at 1.24 μg/μl) 1 h
prior to testing. All testing was carried out at 4 and
16 weeks after tibia fracture.
Hindpaw nociception
To measure mechanical allodynia in the rats, an up-down
von Frey testing paradigm was used as we have previously
described [17, 35, 36]. Rats were placed in a clear plastic
cylinder (20 cm in diameter) with a wire mesh bottom
and allowed to acclimate for 15 min. The paw was tested
with one of a series of eight von Frey hairs ranging in
stiffness from 0.41 to 15.14 g. The von Frey hair was
applied against the hindpaw plantar skin at approximately
midsole, taking care to avoid the tori pads. The fiber was
pushed until it slightly bowed. Hindpaw withdrawal from
the fiber was considered a positive response. The initial
fiber presentation was 2.1 g, and the fibers were presented
according to the up-down method of Dixon to generate
six responses in the immediate vicinity of the 50 % thresh-
old. Stimuli were presented at an interval of several
seconds. In addition, to measure hindpaw unweighting, an
incapacitance device (IITC Inc. Life Science, Woodland,
CA, USA) was used. The rats were manually held in a
vertical position over the apparatus with the hindpaws
resting on separate metal scale plates, and the entire
weight of the rat was supported on the hindpaws. The
duration of each measurement was 6 s, and ten consecu-
tive measurements were taken at 60-s intervals. Eight
readings (excluding the highest and lowest ones) were
averaged to calculate the bilateral hindpaw weight-bearing
values.
Hindpaw temperature
The room temperature was maintained at 23 °C, and
humidity ranged between 25 and 45 %. The temperature
of the hindpaw was measured using a fine wire thermo-
couple (Omega, Stanford, CT, USA) applied to the paw
skin, as previously described [17, 35, 36]. The investiga-
tor held the thermistor wire using an insulating Styro-
foam block. Three sites were tested over the dorsum of
the hindpaw; the space between the first and second
metatarsals (medial), the second and third metatarsals
(central), and the fourth and fifth metatarsals (lateral).
After a site was tested in one hindpaw, the same site was
immediately tested in the contralateral hindpaw. The
testing protocol was medial dorsum right then left,
central dorsum right then left, lateral dorsum right then
left, medial dorsum left then right, central dorsum left
then right, and lateral dorsum left then right. The six
measurements for each hindpaw were averaged for the
mean temperature.
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Hindpaw thickness
A laser sensor technique was used to determine the
dorsal-ventral thickness of the hindpaw, as we have pre-
viously described [35]. For laser measurements, each rat
was briefly anesthetized with isoflurane and then held
vertically so the hindpaw rested on a table top below the
laser. The paw was gently held flat on the table with a
small metal rod applied to the top of the ankle joint.
Using optical triangulation, a laser with a distance meas-
uring sensor was used to determine the distance to the
table top and to the top of the hindpaw at a spot on the
dorsal skin over the midpoint of the third metatarsal,
and the difference was used to calculate the dorsal-
ventral paw thickness. The measurement sensor device
used in these experiments (4381 Precicura, Limab,
Goteborg, Sweden) has a measurement range of 200 mm
with a 0.01-mm resolution.
Epidermal thickness
This experiment determined whether fracture chronic-
ally increases epidermal thickness. four and sixteen-week
post-fracture rats were anesthetized with isoflurane and
then transcardially perfused with 4 % paraformaldehyde
in phosphate-buffered saline (PBS, pH 7.4); the dorsal
hindpaw skin including sub-dermal layers was immedi-
ately removed and post-fixed in 4 % paraformaldehyde
(PFA) for 2 h; then, the tissues were treated with 30 %
sucrose in PBS at 4 °C before embedding in OCT.
Following embedding, 20-μm slices were made using a
cryostat and mounted onto Superfrost microscope slides
(Fisher scientific, Pittsburgh, PA). All sections were
stored at −70 °C until use for immunohistochemistry.
Frozen sections were permeabilized and blocked with
PBS containing 10 % donkey serum and 0.3 % Triton X-
100 prior to primary antibody incubation. Sections were
incubated with a pan-keratinocyte marker recognizing
both the acidic and basic (types I and II) subfamilies of
cytokeratins for keratinocyte labeling, and fluorescent
immunohistochemistry and confocal microscopy were
performed as previously described [19]. Epidermal thick-
ness measurements were made using LSM Image Browser
from Zeiss LSM Data Server. A blinded observer selected
four to eight sections from each skin specimen, and four
to eight thickness measurements were made in each sec-
tion to derive a mean score for that sample. The individual
mean scores were then used to calculate the mean thick-
ness and standard error of the mean for the control limbs
and the fracture limbs at 4 and 16 weeks post injury.
Homogenization procedure and enzyme immunoassay for
TNFα, IL-1β, IL-6, and NGF
Rat hindpaw dorsal skin and ipsilateral spinal cord of
lumbar enlargement section were collected after behav-
ioral testing or at time points as indicated and frozen
immediately on dry ice. Skin and spinal cord tissues
were cut into fine pieces in ice-cold phosphate-buffered
saline (PBS), pH 7.4, containing protease inhibitors
(aprotinin [2 μg/ml], leupeptin [5 μg/ml], pepstatin
[0.7 μg/ml], and PMSF [100 μg/ml]; Sigma, St. Louis,
MO, USA) followed by homogenization using a rotor/
stator homogenizer. Homogenates were centrifuged for
5 min at 14,000 g, and at 4 °C. Supernatants were trans-
ferred to fresh pre-cooled Eppendorf tubes. Triton X-100
(Boehringer Mannheim, Germany) was added at a final
concentration 0.01 %. The samples were centrifuged again
for 5 min at 14,000 g at 4 °C. The supernatants were
aliquoted and stored at −80 °C. TNFα, IL-1β, and IL-6
protein levels were determined using EIA kits (R&D Sys-
tems, Minneapolis, MN, USA). The NGF concentrations
were determined using the NGF Emax® ImmunoAssay
System kit (Promega, Madison, WI, USA) according to
the manufacturer’s instructions. The optical density (OD)
of the reaction product was read on a microplate reader at
450 nm. The concentrations of TNFα, IL-1β, IL-6, and
NGF proteins were calculated from the standard curve at
each assay. Positive and negative controls were included
in each assay. Each protein concentration was expressed
as picogram per milligram total protein. Total protein
contents in all tissue extracts were measured by the
Coomassie Blue Protein Assay Kit (Bio-Rad, Hercules,
CA).
Enzyme immunoassay procedure for sciatic nerve SP
The aim of this experiment was to determine whether
fracture induced up-regulated SP protein expression in
the sciatic nerve at 4 and 16 weeks post fracture. The right
sciatic nerve was collected under isoflurane anesthesia,
immediately frozen, and weighed. Nerve samples were
minced in 1 ml of 3:1 ethanol/0.7 M HCl and homoge-
nized for 20 s. The homogenates were shaken for 2 h at
4 °C and centrifuged at 3000 g for 20 min at 4 °C. The
supernatant was frozen and lyophilized, and the lyophi-
lized product was stored at −80 °C. All nerve samples were
assayed in duplicate using an EIA kit to determine SP
levels (Assay Designs, Ann Arbor, MI) following the
manufacturer’s protocols.
SP-facilitated extravasation in fracture rats
This experiment tested the hypothesis that tibia fracture
facilitates SP-evoked extravasation responses in the
injured hindlimb at 4 and 16 weeks after injury, when
compared with the normal controls. Five minutes
after injection of Evans blue dye (50 mg/kg in Ringers,
Sigma), SP (10 μg/kg, Sigma) was injected intravenously
into the internal jugular vein. Five minutes after SP injec-
tion, the rats were anesthetized with isoflurane, transcar-
dially perfused as previously described, and the plantar
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and dorsal skin on each hindpaw was collected for dye
content determination [16].
Western blotting
These experiments tested the hypothesis that tibia fracture
with cast immobilization can induce chronic increases in
the NK1-receptor protein in the hindpaw skin and spinal
cord of lumbar enlargement. At 4 or 16 weeks after
fracture, the ipsilateral hindpaw dorsum skin was collected
under isoflurane anesthesia and was homogenized in
modified RIPA buffer (50 mM Tris–HCl, 150 mM NaCl,
1 mM EDTA, 1 % Igepal CA-630, 0.1 % SDS, 50 mM NaF,
and 1 mM NaVO3) containing protease inhibitors (aproti-
nin [2 μg/ml], leupeptin [5 μg/ml], pepstatin [0.7 μg/ml],
and PMSF [2 mM]; Sigma, St. Louis, MO, USA). The
homogenate was centrifuged at 13,000g for 30 min at
4 °C. Total protein concentration of the homogenate
was measured using a Coomassie Blue Protein Assay
(Bio-Rad, Hercules, CA) and normalized against BSA
protein standards (Pierce, Rockford, IL). The supernatant
was subjected to Western blot analysis using our previ-
ously described methods [16] to elucidate changes in
NK1-receptor protein expression in the skin or spinal
cord. Equal amounts of protein (30 μg) were subjected to
SDS-PAGE (12 % Tris–HCl acrylamide gel, Bio-Rad,
Hercules, CA) and electrotransferred onto a polyvinyli-
dene difluorided membrane (Millipore). The blots were
blocked with 5 % non-fat dry milk in Tris-buffered saline,
incubated with goat anti-rat NK1R primary antibody over-
night at 4 °C and further incubated with HRP-conjugated
secondary antibody (Santa Cruz Biotechnology, Santa
Cruz, CA) for 1 h at room temperature. After washing
in TBST three times, the blot was then incubated in
ECL plus chemoluminescence reagents (Amersham, Pis-
cataway, NJ) and scanned by PhosphoImager (Typhoon,
GE Healthcare), and the band intensity was analyzed
using ImageQuant 5.2 software (Molecular Dynamics, Pis-
cataway, NJ) and normalized with the corresponding in-
ternal loading control band, β-actin. The specific protein/
actin band intensity ratio represents the change of the spe-
cific protein.
Study design
To study the acute and chronic changes in nociceptive
behavior, vascular signs, and inflammatory responses, rats
were randomly assigned to four primary experimental
cohorts: 4-week controls, 4-week post fracture, 16-week
controls, and 16-week post fracture. Control rats received
no fracture or other treatments. At the designated time
point, all cohorts were tested for bilateral hindpaw mech-
anical nociceptive withdrawal thresholds to von Frey
fibers, weighting, hindpaw temperature, and hindpaw
thickness as well as intravenous SP-induced hindpaw
extravasation. Ipsilateral to the fracture, the hindpaw
skin, as well as sciatic nerve and lumbar spinal cord
was collected and stored for determination of TNFα,
IL-1β, IL-6, and NGF protein, as well as SP and NK1
receptor levels, respectively.
Separate cohorts of fracture rats at the 4- and 16-week
time points were treated systemically with vehicle (i.p. or
s.c.), LY303870 (i.p.), anakinra (s.c. pump or i.p. injection),
or anti-NGF (s.c. injection). Anakinra and anti-NGF are
large molecules with poor CNS penetration; thus, we
assumed that these treatments inhibited peripheral in-
flammatory mechanisms in the injured limb without
affecting CNS inflammatory changes. Additional frac-
ture rats at the 4- and 16-week time points were treated
intrathecally with either vehicle, LY303870, anakinra, or
anti-NGF to test the hypothesis that spinal cord SP signal-
ing, IL-1β, and NGF contribute to pathological signs of
CRPS in the acute and chronic phases. Each cohort
was tested for bilateral hindpaw mechanical nocicep-
tive withdrawal thresholds to von Frey fibers, unweight-
ing, warmth, and edema.
Statistical analysis
Statistical analysis was accomplished using a one-way
analysis of variance (ANOVA) followed by Neuman-
Keuls multiple comparison test to compare among all
cohorts. All data are presented as the mean ± standard
error (SE) of the mean, and differences are considered
significant at a P value less than 0.05 (Prism 5, GraphPad
Software, San Diego, CA, USA).
Hindpaw temperature, thickness, and mechanical noci-
ceptive threshold data were analyzed as the difference
between the fracture side (right, R) and the contralateral
untreated side (left, L). Right hindpaw weight-bearing data
were analyzed as a ratio between twice the right hindpaw
weighting and the sum of the right (R) and left (L) hind-
paw values ([2R/(R + L)] × 100 %).
Results
The time course of nociceptive, vascular, and trophic
changes in the CRPS model
The nociceptive and vascular effects of tibia fracture
followed by cast immobilization were examined in control
and fracture rats at 4 weeks and at 16 weeks. Fracture-
induced hindpaw mechanical allodynia at 4 weeks post
fracture, and subsequently, more than 90 % of the allody-
nia persisted (Fig. 1a) at 16 weeks. In contrast, most frac-
ture-induced hindlimb unweighting had recovered by
16 weeks, indicating different mechanisms may be re-
sponsible for these two nociceptive responses (Fig. 1b).
Although only approximately 10 % unweighting deficit
(2R*100 %/[R + L]) remained at 16 weeks, the actual body-
weight bearing deficit (R-L, with average body weight
approximately 500 g) was very significant as in pain.
Fracture-induced hindpaw vascular abnormalities at
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4 weeks, including warmth (5.65 °C increase in skin
temperature, Fig. 1c), and edema (hindpaw thickness
increased by 0.8 mm, Fig. 1d). These hindpaw vascular
changes subsided completely by 16 weeks. Similarly, epi-
dermal thickness was increased at 4 weeks post fracture
(47 μm increase in hindpaw epidermal thickness), but not
at 16 weeks (Fig. 1e).
Increased cutaneous cytokine and neurotrophin levels at
4 weeks but not 16 weeks post fracture
Increased levels of the cytokines TNFα, IL-1β, IL-6, and
the neurotrophin NGF were observed in the hindpaw skin
of the affected limb at 4 weeks after fracture (Fig. 2a–d).
All of these cutaneous inflammatory changes had returned
to baseline by the 16-week time point.
Increased cutaneous SP signaling at 4 weeks but not
16 weeks after fracture
Previously, we reported enhanced SP-evoked extravasa-
tion as a result of post-junctional facilitation of SP sig-
naling in the fracture model at the 4-week time point
[16]. Here, we observed, similar to previous data, that SP
intravenous injection caused significantly more Evan’s
blue extravasation at 4 weeks post fracture than in con-
trol rats (Fig. 3a). However, this effect subsided by
16 weeks. In addition, fracture induced a 119 % increase
in SP expression in the sciatic nerve at 4 weeks, but SP
levels had declined by 20 % at 16 weeks post fracture
(Fig. 3b). In addition, NK1-receptor expression in the
skin increased at 4 weeks post fracture but returned to
control levels at 16 weeks (Fig. 3c, d).
Systemic treatment with LY303870, anakinra, anti-NGF
reversed fracture-induced nociceptive and vascular
changes at 4 weeks after fracture
To assess SP, IL-1β, and NGF-mediated contributions to
the nociceptive and vascular changes in this model at 4
(Fig. 4) and 16 weeks (Fig. 5) after fracture, rats were
systemically treated with the NK1-receptor antagonist
LY303870 (30 mg/kg/day i.p. for 7 days and one add-
itional last dose given at 1 h prior to testing), the IL-1β
inhibitor anakinra (via a pump at 10 mg/kg/day for
28 days, s.c.), or the NGF inhibitor anti-NGF (one dose
s.c. injection, 10 mg/kg at 7 days prior to testing). The
administration of LY303870 or anakinra to 4-week
post-fracture rats effectively abolished hindpaw allody-
nia (Fig. 4a). In addition, anti-NGF also reduced allody-
nia by 70 %. A similar trend was found in reversing
unweighting by LY303870, anakinra, and anti-NGF anti-
body (Fig. 4b). The NK1-receptor antagonist, LY303870,
completely reversed unweighting, and the IL-1β and NGF
inhibitors each significantly reduced the unweighting
response in the rats at 4 weeks after fracture. All three
agents reduced the temperature difference between the
Fig. 1 Differential recovery of nociceptive and vascular abnormalities
in the rat CRPS. The measurements displayed were made at 4 and
16 weeks after fracture. a Tibia fracture-induced mechanical allodynia
to von Frey testing. b Hindpaw unweighting. c Hindpaw warmth.
d Hindpaw edema. e Epidermal thickness. Measurements for a–d
represent the difference between the fracture ipsilateral side and the
contralateral paw. The values displayed in panel b represent weight-
bearing on the fracture hindlimb as a ratio to 50 % of bilateral hindlimb
loading. e Changes in dorsal hindpaw epidermal thickness at 4 and
16 weeks after fracture. Immunostaining of keratin (a keratinocyte
marker) was performed in dorsal hindpaw skin sections from control
rats (n = 7), and from the ipsilateral hindpaws of fracture rats at 4
(n = 8) and 16 weeks (n = 8) post injury. Data are analyzed to
compare fracture at 4 weeks versus no-fracture control cohorts
and fracture at 16 weeks versus fracture at 4 weeks cohorts using
one-way analysis of variance (ANOVA) followed by Neuman-Keuls
multiple comparison test. *P < 0.05, **P < 0.01, and ***P < 0.001,
fracture at 4 weeks (panels a–d, n = 6) versus control rats (panels
a–d, n = 6); #P < 0.05, ##P < 0.01, and ###P < 0.001, fracture at
16 weeks (panels a–d, n = 5) versus fracture at 4 weeks cohorts
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Fig. 2 Cytokine and NGF levels in hindpaw skin were elevated at 4 weeks and returned to normal levels by 16 weeks after fracture. TNFα (a),
IL-1β (b), IL-6 (c) and nerve growth factor (NGF) (d) levels in hindpaw skin was measured by specific EIAs at 4 and 16 weeks after fracture. Data
are expressed as mean values (pg/mg protein) ± standard error (SE) and analyzed using one-way ANOVA followed by Neuman-Keuls multiple
comparison test to compare different time points. *P < 0.05, **P < 0.01, and ***P < 0.001 versus control; #P < 0.05, ##P < 0.01, and ###P < 0.001 versus
fracture at 4 weeks, (n = 8 per cohort)
Fig. 3 Fracture-facilitated SP-induced Evan’s blue extravasation at 4 weeks but not 16 weeks. a Evan’s blue dye extravasation in rats (control cohort,
n = 5; FX- 4 WK, n = 5; FX- 16 WK, n = 7) after SP injection. b Fracture induced SP expression in sciatic nerve tissue at 4 and 16 weeks after fracture
(n = 8 per cohort). c Fracture-induced NK1-receptor expression in hindpaw skin at 4 and 16 weeks after fracture (n = 3 per cohort). d Representative
Western blot of skin NK1 receptor and actin. Data are expressed as mean values (pg/mg protein or fold change) ± standard error (SE) and analyzed
using one-way ANOVA followed by Neuman-Keuls multiple comparison test to compare control and fracture cohorts at different time points.
*P < 0.05, **P < 0.01, and ***P < 0.001 versus control; #P < 0.05, ##P < 0.01, and ###P < 0.001 versus fracture at 4 weeks
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hindpaws of the 4-week fracture rats (Fig. 4c), with the
effect size ranging from 30 to 50 %. Tibia fracture also
induced edema, indicated as an increase in hindpaw thick-
ness of 1.44 mm in the ipsi- versus contralateral paws.
The effects of LY303870, anakinra, and anti-NGF on
edema did not reach statistical significancel, though there
did appear to be strong trends towards reduced paw
thickness.
Systemic treatment with LY303870, anakinra, or anti-NGF
had minimal effect on nociceptive and vascular changes
at 16 weeks after fracture
To study the effects of SP, IL-1β, and NGF signaling on
nociceptive and vascular changes in the phase of the
model resembling chronic CRPS, rats were fractured and
casted for 4 weeks, followed by cast-removal and recov-
ery for additional 12 weeks. When LY303870 (same dose
as Fig. 4) and anti-NGF (same dose as Fig. 4) were
administered between 15 and 16 weeks after fracture,
only LY303870 showed a significant effect on von Frey
allodynia (Fig. 5a), and the effect size was reduced dramat-
ically compared with the 4-week results. At 16 weeks,
systemic treatments with LY303870 and anti-NGF (Fig. 5a)
lost more than 50 % of their anti-nociceptive effects
observed at 4 weeks (Fig. 4a) post fracture. In addition,
skin cytokine concentrations at 16 weeks, including IL-1β,
declined from 4 weeks post fracture (Fig. 2), but all spinal
cord cytokine concentrations at 16 weeks remained high
Fig. 4 Systemic administration of LY303870, anakinra, and anti-NGF reversed fracture-induced nociceptive and vascular responses at 4 weeks
after fracture. LY303870 (30 mg/kg/day i.p.) was administered for 7 days between 3 and 4 weeks post fracture. Anakinra was administered at
10 mg/kg/day s.c. in a pump for 28 days prior to testing at 4 weeks post fracture. Anti-NGF (10 mg/kg s.c.) was administered at 7 days prior to
testing at 4 weeks post fracture. a Tibia fracture induced mechanical allodynia to von Frey testing at 4 weeks (control cohort, n = 10; FX- 4 WK,
n = 10), and LY303870 (n = 8), anakinra (n = 10), and anti-NGF (n = 10) all reduced this sensitization. b At 4 weeks, unweighting developed in the
ipsilateral hindpaw in fracture rats, and again, the test agents reduced the unweighting response. c Warmth was observed in fracture rats at
4 weeks, but fracture rats treated with LY303870, anakinra, or anti-NGF showed reduced temperature differences. d Edema indicated as an increase
in hindpaw thickness was found at 4 weeks after fracture. Cohorts of rats treated with each of the test agents failed to show statistically significant
changes in edema. Measurements for a, c, and d represent the difference between the fracture ipsilateral side and the contralateral paw.
Measurements displayed in b represent weight-bearing on the fracture hindlimb as a ratio to 50 % of bilateral hindlimb loading. Data are
expressed as mean values ± standard error (SE) and analyzed to compare fracture at 4 weeks versus non-fracture control cohorts and fracture with
treatments versus fracture at 4 weeks cohorts using one-way ANOVA followed by Neuman-Keuls multiple comparison test. *P < 0.05, **P < 0.01, and
***P < 0.001, fracture at 4 weeks versus control rats; #P < 0.05, ##P < 0.01, and ###P < 0.001, fracture with treatments versus fracture at 4 weeks
(panels b–d, control cohort, n = 6; FX- 4 WK, n = 8; FX- 4 WK + LY303870, n = 8; FX- 4 WK + anakinra, n = 10; FX- 4 WK + anti-NGF, n = 7)
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(Fig. 6) and close to the peak concentration at 4 weeks
post fracture. These data suggested that SP signaling
and inflammation in the spinal cord at the central
level might contribute to nociceptive abnormalities at
16 weeks. Thus, it became important to unveil the effects
of these agents at the spinal level at 16 weeks. As shown
in Fig. 5b, at 16 weeks, post-fracture hindpaw unweighting
was approximately 10 %, and both LY303870 and anti-
NGF had significant analgesic effects in unweighting.
Vascular abnormalities had resolved by 16 weeks post
fracture (Fig. 1). We did not undertake 28-day infu-
sions of anakinra in the 16-week-fracture rats as we
had at 4 weeks (Fig. 4), provided the younger rats were in
cast for 4 weeks. Those animals would have been treated
in a less chronic phase (12–16 weeks post fracture) by the
time of assessment making data interpretation tenuous.
We did, however, administer anakinra as a single i.p. bolus
of 100 mg/kg at 1 h prior to testing at 16 weeks post
fracture (Fig. 5) as a comparison to the treatment with
anakinra via i.t. injection (Fig. 8c, d). At 16 weeks post
Fig. 5 Systemic administration of LY303870, anakinra, and anti-NGF poorly reversed fracture-induced nociceptive responses at 16 weeks. Vehicle,
LY303870, anakinra, or anti-NGF was administered between 15 and 16 weeks post fracture, and the rats were tested at 16 weeks post fracture.
LY303870 (same treatment as Fig. 4) was injected for 7 days prior to testing, anakinra (100 mg/kg i.p.) was injected once at 1 h prior to testing,
and anti-NGF (same treatment as Fig. 4) was injected once at 7 days prior to testing at 16 weeks post fracture. a Mechanical allodynia tested by
von Frey fibers persisted to 16 weeks post fracture. LY303870, but not anakinra or anti-NGF, reversed fracture-induced allodynia at the 16-week
time point. b Approximately 10 % unweighting remained at 16 weeks post fracture. Both LY303870 and anti-NGF reversed this remaining hindpaw
unweighting. Data are expressed as mean values ± standard error (SE) and analyzed to compare fracture at 16 weeks versus non-fracture control
cohorts and fracture with treatments versus fracture at 16 weeks cohorts using one-way ANOVA followed by Neuman-Keuls multiple comparison
test. *P < 0.05, **P < 0.01, and ***P < 0.001 versus control rats; #P < 0.05, ##P < 0.01, and ###P < 0.001, fracture with treatments versus fracture at
16 weeks (control cohort, n = 10; FX- 4 WK, n = 8–10; FX- 4 WK + LY303870, n = 8–9; FX- 4 WK + anakinra, n = 6; FX- 4 WK + anti-NGF, n = 6–8)
Fig. 6 Cytokine and NGF levels in spinal cord tissue 4 and 16 weeks after fracture. The data displayed represent TNFα (a), IL-1β (b), IL-6 (c), and
nerve growth factor (NGF) (d) levels in lumbar spinal cord tissue ipsilateral to fracture at 4 and 16 weeks post fracture. Data are expressed as mean
values (pg/mg protein) ± standard error (SE) and analyzed using one-way ANOVA followed by Neuman-Keuls multiple comparison test to compare
control and fracture cohorts at different time points. *P < 0.05, **P < 0.01, and ***P < 0.001 versus control; #P < 0.05, ##P < 0.01, and ###P < 0.001 versus
fracture at 4 weeks (panels a, c, and d, n = 8 per cohort; panel b, n = 6 per cohort)
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fracture, anakinra i.t. (Fig. 8) showed an anti-nociceptive
effect on allodynia and unweighting; however, anakinra
i.p. did not (Fig. 5). Such a dose (anakinra, i.p. 100 mg/kg)
was determined previously in a 4-week (acute stage)-
fracture study in which 10 mg/kg/day of anakinra
treatment was administered for 7 days prior to testing
in a separate group of fracture rats. The 7-day treatment
with anakinra yielded 50 % anti-allodynia and 50 % anti-
unweighting effects at 4 weeks (data not shown) as
compared to the 28-day treatment yielding 100 % anti-
allodynia and 50 % anti-unweighting effects at 4 weeks
(Fig. 4a, b). That is, a total dose of 70 mg over a 7-day
period is sufficient to partially reduce fracture-induced
nociceptive abnormalities at 4 weeks.
Levels of cytokines, NGF, and NK1 receptor remain
elevated in spinal cord tissue at 16 weeks after fracture
At 16 weeks post fracture, nociceptive changes persisted
while the effects of systemic treatments with LY303870,
anakinra, and anti-NGF tended to lose analgesic efficacy.
Anakinra and anti-NGF are large molecules with poor
CNS penetration. Therefore, we hypothesized that noci-
ceptive sensitization might be supported by persistent
changes in these mediators at the spinal level. We there-
fore measured levels of the cytokines TNFα, IL-1β, and
IL-6 as well as NGF in the spinal cord tissue of lumbar
enlargement section ipsilateral to tibia fracture at 4 and
16 weeks post fracture. We found that the protein levels
of all these mediators in spinal cord were significantly
elevated at both 4 and 16 weeks post fracture, with the
exception of IL-6 whose elevation at 16 weeks was not
significant (Fig. 6). Only for NGF was there significantly
less mediator present in spinal cord tissue at 16 versus
4 weeks (Fig. 6d). We went on to examine changes in
SP/NK1 signaling molecules. At 4 weeks, both SP
(Fig. 7a) and NK1-receptor (Fig. 7b) levels were elevated
in spinal cord tissue ipsilateral to tibial fracture. While
the elevation in SP content significantly normalized by
16 weeks, the elevation in expression of the NK1 recep-
tor remained significant.
Spinal NK1 receptor, IL-1β, and NGF signaling contribute
to nociceptive changes in both the acute and chronic
phases of the fracture model
Based on the evidence that NK1 receptor, cytokine, and
neurotrophin levels remain elevated in spinal tissue
throughout the 16-week time course of the fracture
model, we next hypothesized that blocking the spinal
effects of these signaling molecules might be effective in
reducing nociceptive sensitization in both phases of the
model. We therefore administered LY303870, anakinra,
and anti-NGF intrathecally to the rats both 4 and
16 weeks after tibia fracture. The data presented in Fig. 8
show that each of these agents was effective in reducing
hindpaw allodynia and hindpaw unweighting in both the
acute (4 weeks) and chronic (16 weeks) phase rats at the
spinal cord level, as opposed to the minimal systemic
effects of anakinra and anti-NGF in the chronic phase
(Fig. 5).
The frequency of specific CRPS-like changes in the tibia
fracture/cast immobilization model changes over time
In these studies, we followed four CRPS-like changes
manifest in the fracture rats similar to those used in the
Fig. 7 The elevation of substance P and NK1R levels in ipsilateral lumbar spinal cord tissue in fracture rats. a Substance P in spinal cord in control
rats (n = 15) was elevated in response to fracture at 4 weeks (n = 14) but subsided by 16 weeks (n = 16) post fracture. b NK1-receptor (NK1R) levels
were elevated in the lumbar enlargement ipsilateral spinal cord at 4 weeks by 2.2-fold and remained significantly elevated by 1.8-fold at 16 weeks
post fracture (n = 3 per cohort). c The NK1R band intensities were normalized against actin band intensities. Data are expressed as mean values ±
standard error (SE) and analyzed using one-way ANOVA followed by Neuman-Keuls multiple comparison test to compare control and fracture
cohorts at different time points. *P < 0.05, **P < 0.01, and ***P < 0.001 versus control; #P < 0.05, ##P < 0.01, and ###P < 0.001 versus fracture at 4 weeks
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Budapest criteria for the diagnosis of CRPS [37]. Signs
as well as criteria and prevalence of each sign at 4 and
16 weeks post fracture are listed in Table 1. Those
changes included nociceptive (hindpaw allodynia, hind-
paw unweighting) and vascular (warmth and edema)
features. The data presented in Fig. 9 demonstrate that
at 4 weeks post fracture, the majority of the rats devel-
oped three (43 %) to four (51 %) CRPS-like signs. At
16 weeks, only 18 % of the fracture rats completely
recovered, and 60 % of fracture rats still exhibited at
Fig. 8 Intrathecal injections of LY303870, anakinra, and anti-NGF at 4 and 16 weeks post fracture reversed allodynia and unweighting. LY303870
(10 μl at 20 μg/μl, 30 min prior to testing), anakinra (10 μl at 10 μg/μl, 1 h prior to testing), and anti-NGF (10 μl at 1.24 μg/μl, 1 h prior to testing)
were administered via intrathecal injection. a At 4 weeks, fracture induced allodynia and unweighting. Treatments with LY303870, anakinra, and
anti-NGF reduced fracture-induced allodynia by 52, 84, and 62 %, respectively. b The same treatments reduced unweighting by 58, 60, and 60 %,
respectively. c At 16 weeks, allodynia and unweighting were still significant. Treatments with LY303870, anakinra, and anti-NGF reduced fracture-
induced allodynia by 54, 79, and 67 %, respectively. d The same treatments at 16 weeks post fracture reduced unweighting by 88, 61, and 67 %,
respectively. Measurements for allodynia and unweighting were carried out and calculated as described for Fig. 1. Data are expressed as mean
values ± standard error (SE) and analyzed using one-way ANOVA followed by Neuman-Keuls multiple comparison test to compare control and
fracture at 4 weeks cohorts (control, n = 6; FX- 4 WK, n = 7; FX- 4 WK + LY303870, n = 7; FX- 4 WK + anakinra, n = 8; FX- 4 WK + anti-NGF, n = 8) as
well as fracture with the treatment versus fracture cohorts at 16 weeks (control, n = 6; FX- 16 WK, n = 8; FX- 16 WK + LY303870, n = 8; FX- 16 WK+
anakinra, n = 6; FX- 16 WK + anti-NGF, n = 8). *P < 0.05, **P < 0.01, and ***P < 0.001 versus control; #P < 0.05, ##P < 0.01, and ###P < 0.001 versus fracture at
4 or 16 weeks
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least one of the four CRPS-like signs. As shown in
Table 1, allodynia was by far the most durable of the
CRPS-like changes over time.
Discussion
Complex regional pain syndrome (CRPS) is a pain
syndrome of modest prevalence in the overall population
but has a relatively high incidence after injuries and
surgeries to the limbs. Fracture of an extremity followed
by immobilization is a particularly common set of circum-
stances leading to CRPS. The acute phase of the syndrome
frequently involves an erythematous, warm, swollen, pain-
ful limb, all signs of acute neurogenic inflammation [38].
While some patients retain these signs of inflammation, it
is more common for the warmth and swelling to resolve
over the course of months with a normal or even cool
atrophic but still painful limb in the chronic phases of the
condition [39]. Thus CRPS is often thought to have an
acute or “warm” phase followed by a more chronic “cold”
phase. This difference is seldom considered when provid-
ing therapeutic interventions, though the mechanisms
supporting the condition appear to be changing. Our earl-
ier studies showed that gene transcription patterns within
the CNS change as fracture mice progress from the acute
to the chronic stages of the syndrome [40]. Moreover,
centrally mediated signs and symptoms become more
common in the chronic phases of the condition such as
cognitive changes, mood alterations, and motor function
disturbances. Thus, we hypothesized that we would ob-
serve a shift in the location of mediators driving the
CRPS-like changes of our model from the periphery to
the spinal cord over time. The fundamental observations
of our studies were: (1) cytokines and NGF are elevated in
skin at relatively acute time points after tibia fracture and
immobilization, but these normalize over time; (2) hind-
paw edema, keratinocyte proliferation, and increase in
peripheral SP and NK1-receptor expression resolve as the
condition becomes more chronic; (3) spinal cord cyto-
kines, NGF, SP, and NK1-receptor levels are increased in
the early post-fracture period, and most of these spinal in-
flammatory changes persist in the chronic post fracture
period; (4) spinal cord SP, cytokine, and NGF signaling
support nociceptive sensitization at both acute and
chronic time points; and (5) mechanical allodynia is the
most durable of the CRPS-like changes exhibited by our
model over time.
A great deal of attention has been paid to the presence
of pain and inflammation-related mediators in the skin
of patients with CRPS. Some of the most compelling
studies have involved the analysis of fluid from suction
blisters made on the skin of CRPS patients. Numerous
cytokines including TNFα, IL-6, and others have been
discovered at elevated levels [41, 42]. While the relation-
ship of mediator abundance to CRPS duration has not
been firmly established, it does appear that cytokine
levels may decline over time in some patients [42]. Our
study using human hand surgery patients discovered
elevated levels of skin cytokines and NGF 3–5 weeks
after surgery at the point of cast-removal [43]. Mechan-
ical allodynia, warmth, and edema were all present in
Table 1 Prevalence of CRPS-like signs (allodynia, unweighting, warmth, and edema) observed at 4 weeks and 16 weeks post fracture
in fracture rats. The arbitrary criteria indicate approximately 30-50 % normalization of each measurement.
Signs Allodynia Unweighting Warmth Edema
Criteria

























R right hindpaw, L left hindpaw, FX- 4 WK 4 weeks after fracture, FX- 16 WK 16 weeks after fracture
Fig. 9 Prevalence of CRPS type I-like signs in the rat fracture model.
At 4 weeks post fracture, (n = 37), 5, 43, and 51 % of fracture rats
developed 2, 3, and 4 of the 4 signs, respectively, including allodynia,
unweighting, warmth, and edema. At 16 weeks (n = 38), only 18 %
of the fracture rats completely recovered, and 60 % of fracture rats
still exerted at least 1 of the 4 CRPS type I-like signs
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these patients suggesting that tissue trauma followed by
immobilization may commonly evoke this type of
peripheral inflammatory response, though not all pa-
tients go on to develop chronic CRPS. Additional studies
using a radiolabeled anti-TNF molecule found greatly
enhanced TNF activity in the limbs of CRPS patients
[44]. On the other hand, results from small human trials
using biologic anti-TNF agents are less clear, though en-
couraging results were noted in some patients [45, 46].
The present study monitored the pathological changes
accompanying CRPS-like changes in early (4 weeks) and
later (16 weeks) stages of a rat model. By 16 weeks post
fracture, vasculature abnormalities, including warmth and
edema, recovered as inflammation subsided in skin. Our
data indicate that the processes supporting persistent
sensitization in the late stage animals are likely spinal. This
has implications concerning the tailoring of treatments for
early versus late stage disease. Future experiments might
exploit the individual patterns of recovery both of humans
and laboratory animals to gain insight into the mechanisms
contributing to each of the features of CRPS.
Using mouse and rat tibia fracture/cast immobilization
models, the effects of peripherally restricted anti-cytokine
and anti-NGF have been reported. For example, the
administration of the same anti-IL-1ra agent used in these
studies (anakinra), the anti-TNF agent etanercept, and an
anti-NGF antibody all effectively reduced nociceptive
changes [28, 34, 47]. Importantly, all of those studies
involved measurements made during the acute phase of
the model. Correspondingly, elevated levels of these
cytokines and NGF were identified in the skin of the
affected limbs. The present group of studies demonstrates
that anti-IL-1β and anti-NGF were effective at 4 weeks
post fracture, but these agents lost effect at 16 weeks after
fracture, despite ongoing nociceptive changes. This corre-
sponded to the resolution of elevated levels of these
mediators in the peripheral tissues. On the other hand,
our data showed both chronic elevations of IL-1β and
NGF in spinal cord tissue, as well as the persistent efficacy
of spinally administered IL-1β and NGF inhibitors in
reversing nociceptive changes. Thus, the relevant pool of
these mediators appears to be located within the CNS in
the more chronic phases of the syndrome. We previously
demonstrated that keratinocytes are the chief peripheral
cell-type producing cytokines and NGF in this model and
in CRPS patients [6, 19], though the central sources of
these mediators have not been identified. Furthermore, as
LY303870, anakinra, and anti-NGF exerted potent anti-
nociceptive effects at 4 weeks in the CRPS rat model, an
important question is whether these treatments can
prevent the development of CRPS when these drugs are
administered immediately or very early on after fracture.
Neurogenic inflammation has well-established roles in
the peripheral manifestations of CRPS. Substance P (SP)
released peripherally from afferent/efferent nerves has
been shown to alter capillary permeability in humans, an
effect that is exaggerated in CRPS-affected limbs [9] and
in animal models of CRPS [16]. These effects are believed
to be mediated through increased NK1-receptor expres-
sion on endothelial cells in the affected limb [8, 16]. In
addition, SP containing fibers penetrate the epidermis.
Activation of the NK1 receptors expressed by keratino-
cytes stimulate these cells to produce cytokines, NGF, and
other mediators capable in turn of interacting with recep-
tors on afferent neurons to support nociception [48].
Earlier work demonstrated that administration of the
selective NK1 antagonist LY303870 during the early weeks
after fracture inhibited nociceptive sensitization, edema,
warmth, keratinocyte proliferation, and the up-regulation
of cytokines in the skin [17, 18, 25].
Because the fracture/cast rats showed a reduction in
hindpaw edema, warmth, keratinocyte proliferation, and
skin cytokine levels over time, we hypothesized periph-
eral SP/NK1 signaling might also diminish over time.
Indeed, at 4 weeks post fracture, SP levels in sciatic
nerve and NK1-receptor levels in the skin were both
elevated. Correspondingly, SP-evoked plasma extravasa-
tion was augmented. Both the expression and plasma
extravasation responses were similar to those of the
control animals by week 16, however. This is additional
evidence for a normalization of peripheral neural
function and response over time, in spite of persistent
nociceptive changes.
In contrast to the expression and functional responses
of peripheral tissues, NK1-receptor levels remained
elevated in ipsilateral lumbar spinal cord tissue through-
out the course of study. Likewise, intrathecal injection of
the NK1-receptor antagonist LY303870 reduced noci-
ceptive sensitization at both the 4- and 16-week time
points to approximately the same degree (but systemic-
ally administered LY303870 appeared to lose analgesic
efficacy over time). The NK1 receptor is densely
expressed on spinal cord nociceptive projection neurons.
Using both pharmacological and neuroablative techniques,
it has been shown that spinal NK1-expressing neurons are
critical components of nociceptive signaling in many
pain models [24, 49, 50]. Though there is some evi-
dence for the local spinal production of SP, spinal
NK1 receptors are generally felt to respond to SP re-
leased from the central terminals of primary afferent
nerves. Thus, central NK1-mediated signaling may be at
least partially responsible for the persistent nociceptive
sensitization seen in this model. It should be mentioned
that NK1-receptor antagonists with good CNS penetrance
have not been proven to be effective analgesics in humans,
though they do have potent antiemetic properties [51].
We are unaware of a trial of an NK1-receptor antagonist
in human CRPS patients, however.
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Conclusions
In these studies, we followed cytokine, neurotrophin, and
neuropeptide contributions to the nociceptive and vascu-
lar CRPS-like features of a well-characterized fracture/
cast model of CRPS. We found evidence of an initially
peripherally driven set of processes centralizing to sup-
port persistent nociception 16 weeks after the tibia frac-
ture. The gradual loss of the peripheral vascular changes
and keratinocyte proliferation, with ongoing nociceptive
sensitization, is reminiscent of the transition of warm- to
cold-phase CRPS in patients. These observations place
emphasis on the targeting of peripheral processes during
the acute phases of CRPS, though central processes may
be the better targets for chronic CRPS sufferers.
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